This mobile-first microlearning module reviews key updates in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ESC Heart Failure 2026, with a focused emphasis on underrecognized hereditary ATTR-CM and the p.Val142Ile (V142I) variant. Through interactive evidence reviews, congress data interpretation, and case-based decision-making, learners will examine emerging findings related to disease recognition, biomarker stabilization, outpatient worsening heart failure events, and variant-specific treatment considerations across approved disease-modifying therapies.

Designed for busy clinicians, this interactive microlearning activity integrates late-breaking congress evidence with practical clinical application to support earlier recognition of ATTR-CM in historically underserved and underdiagnosed populations, particularly African American patients with hereditary disease. Learners will engage with evolving therapeutic data, interpret clinically relevant outcomes, and apply evidence-informed strategies to diagnosis, treatment selection, and longitudinal management in real-world practice.

This educational initiative is designed for cardiologists, including general cardiologists, heart failure specialists, and electrophysiologists, as well as internal medicine physicians, primary care clinicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the recognition and management of transthyretin amyloid cardiomyopathy.

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.